Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for breast cancer and related endocrine-driven cancers. Its pipeline centers on palazestrant and OP-3136, with development and future commercialization intended in the United States and other key markets, either independently or with partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueLead endocrine therapy candidate being developed for ER+ breast cancer in multiple settings.
KAT6 inhibitor program being evaluated for combination use in breast cancer.
Preclinical and clinical development activities supporting the pipeline.
Research and development collaborations intended to expand development and commercialization reach.
Customers
Olema does not sell commercial products today; its near-term counterparties are clinical investigators, trial sites, contract manufacturers, licensors, and collaboration partners. If approved, its end customers would be oncologists, hospitals, and cancer treatment centers prescribing therapies for patients with ER+ breast cancer and other endocrine-driven cancers.
They run studies of palazestrant and OP-3136 and enable patient enrollment and data generation.
Partners such as Novartis and Pfizer collaborate on development and may support future commercialization.
CMOs provide drug substance, drug product, labeling, and distribution for clinical supply.
If approved, oncologists and cancer centers would prescribe the therapies to patients with ER+ breast cancer.
Strategy
Olema’s strategy is to advance palazestrant in multiple ER+ breast cancer indications and to develop OP-3136 as a complementary oncology program. The company also seeks collaborations that can accelerate development timelines, broaden capabilities, and improve eventual commercialization reach.
The lead asset is the main value driver and the foundation of the pipeline.
A second clinical program can broaden the pipeline and create combination opportunities.
External partners can add development speed, market access, and commercial infrastructure.
Commercial approval would require reliable API, fill-finish, and packaging capacity.
Geography
Olema is headquartered in the United States and conducts its development activities through a global clinical and manufacturing network. The company expects to commercialize in key markets either alone or with partners, and its risk profile is shaped by international regulatory, supply-chain, and intellectual-property exposure.
Risks
Olema faces the core risks of a clinical-stage biotech: no approved products, dependence on successful trials and regulatory outcomes, and ongoing need for external capital. Its pipeline also depends on third-party manufacturers, intellectual-property protection, and the ability to compete against much larger oncology companies with established development and commercial capabilities.
- No products approved for commercial saleImpact: CriticalLikelihood: High
The company has no product revenue and must prove clinical and regulatory success before commercialization.
Exposure: Entire business model
- Need for additional capitalImpact: HighLikelihood: High
Development-stage operations require ongoing funding for trials, manufacturing, and public-company costs.
Exposure: Pipeline development and commercialization
- Clinical development and regulatory riskImpact: HighLikelihood: High
Trial design, efficacy, safety, and approval decisions determine whether assets can advance.
Exposure: Palazestrant and OP-3136
- Competitive intensity in oncologyImpact: HighLikelihood: Medium
Large pharma and biotech peers may develop similar or superior therapies faster.
Exposure: ER+ breast cancer and endocrine-driven cancers
- Intellectual property protectionImpact: HighLikelihood: Low
Value depends on protecting proprietary compounds and related uses across jurisdictions.
Exposure - Third-party manufacturing dependenceImpact: MediumLikelihood: Medium
The company relies on CMOs for clinical and future commercial supply, creating execution and quality risk.
Exposure
Accounting
Judgemental itemsClinical trial and manufacturing costs are often recognized before invoices are received, requiring estimates.
Impact: Can shift operating expenses between quarters
Employee and director equity awards are a meaningful non-cash expense for a public biotech.
Impact: Affects reported losses and diluted share count
Partner arrangements may require judgment on timing and classification of consideration.
Impact: Can create volatility in reported revenue or other income if applicable
Third-party supply agreements and trial obligations can create accruals and contingent liabilities.
Impact: Affects liabilities and cash requirement disclosures
Similar listed companies
Publicly listed companies with a comparable business focus.
Elite Pharmaceuticals Inc /NV/
ELTP · Pharmaceutical Preparations
Elite Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc.
ORIC · Pharmaceutical Preparations
ORIC Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing cancer therapies designed to overcome treatment resistance.
Processa Pharmaceuticals, Inc.
PCSA · Pharmaceutical Preparations
Atossa Therapeutics, Inc
ATOS · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Last updated: 24/09/2026